Sun Pharma shares decline nearly 5% following Q4 results

The pharma major on Thursday, May 22, reported consolidated gross sales of ₹12,815.6 crore for the quarter ended March 31, 2025 (Q4 FY25), up 8.5% year-on-year (YoY).

Its total revenue from operations came in at ₹12,958.84 crore, up 8.1% against ₹11,982.90 crore registered in the corresponding quarter of the previous fiscal.

The pharma major said in its press release that its India formulation sales stood at ₹4,213 crore, up 13.6%, while US formulation sales came in at US$464 million, down 2.5%.

Further, the company's global speciality sales were at US$295 million, up 8.6%, accounting for 19.9% of Q4 FY25 sales, and emerging markets formulation sales stood at US$261 million, up 6.3% YoY.

Moreover, the press release added that its Rest of World formulation sales came in at US$ 200 million, up 2.0% YoY.

Sun Pharma added that its R&D investments during the quarter under review stood at ₹816.6 crore.

On the operational front, Sun Pharma said that its operating profit, or EBITDA (earnings before interest, taxes, depreciation, and amortisation), stood at ₹3,716.1 crore, up 22.4% YoY. This includes other operating revenues.

EBITDA margin came in at 28.7%. The margin was 25.3% in the year-ago period.

Sun Pharma's adjusted net profit (excluding the exceptional items) for Q4 FY25 was ₹2,889.1 crore, up 4.8% YoY. Reported net profit for the quarter slipped 19% YoY to ₹2,149.9 crore as against ₹2,654.6 crore logged during Q4 FY24.